Celularity Insider Surge: Executives Stack Shares Amid Quiet Gains and Rising Investor Buzz
Insider buying spree at Celularity signals confidence in its placental‑derived NK and CAR‑T trials, yet investors should weigh low earnings and high volatility before adding to their biotech mix.
3 minutes to read